| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Victor L Perez | |
| Daniel R Saban | |||
| Meng C Lin | |||
| Piergiorgio Neri | |||
| Laura M Periman | |||
| P2860 | cites work | Inflammatory Response in Dry Eye | Q93343289 |
| Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease | Q26774853 | ||
| NK cells promote Th-17 mediated corneal barrier disruption in dry eye | Q28730069 | ||
| Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome | Q33592784 | ||
| Goblet Cells Contribute to Ocular Surface Immune Tolerance-Implications for Dry Eye Disease. | Q33755012 | ||
| Mechanisms of action of cyclosporine. | Q33908049 | ||
| Characterization of effector T cells in dry eye disease | Q34065949 | ||
| The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs | Q34165372 | ||
| CCR7 is critical for the induction and maintenance of Th17 immunity in dry eye disease | Q34211406 | ||
| The pathology of dry eye. | Q34391929 | ||
| Coordinated regulation of NK receptor expression in the maturing human immune system. | Q34476273 | ||
| Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study | Q34493904 | ||
| The core mechanism of dry eye disease is inflammation | Q34510429 | ||
| Dry eye as a mucosal autoimmune disease | Q34647761 | ||
| Patient reported differences in dry eye disease between men and women: impact, management, and patient satisfaction | Q35010238 | ||
| The association between dry eye disease and depression and anxiety in a large population-based study | Q35085765 | ||
| The chemokine receptor CCR7 expressed by dendritic cells: a key player in corneal and ocular surface inflammation | Q35145988 | ||
| A novel pro-lymphangiogenic function for Th17/IL-17. | Q35525349 | ||
| T-cell integrins: more than just sticking points | Q35576652 | ||
| The role of the lacrimal functional unit in the pathophysiology of dry eye. | Q35755146 | ||
| Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease | Q35907009 | ||
| Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study | Q36089582 | ||
| The effects of oral and topical corticosteroid in rabbit corneas | Q36123362 | ||
| An inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel endothelium | Q36228128 | ||
| JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells | Q36380244 | ||
| PERSIST: Physician's Evaluation of Restasis(®) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review | Q36444344 | ||
| Autoimmunity at the ocular surface: pathogenesis and regulation | Q36625074 | ||
| Tear cytokine profiles in dysfunctional tear syndrome. | Q36637791 | ||
| IL-17 disrupts corneal barrier following desiccating stress. | Q36676135 | ||
| Getting leukocytes to the site of inflammation | Q36772662 | ||
| CD11a regulates effector CD8 T cell differentiation and central memory development in response to infection with Listeria monocytogenes | Q36804718 | ||
| Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study | Q36877000 | ||
| The role of the integrin LFA-1 in T-lymphocyte migration | Q36877329 | ||
| Autoantibodies contribute to the immunopathogenesis of experimental dry eye disease. | Q46073610 | ||
| Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3). | Q46401944 | ||
| TNF-related activation-induced cytokine enhances leukocyte adhesiveness: induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependent NF-kappaB activation in endothelial cells | Q46561923 | ||
| The Role of Health Anxiety and Depressive Symptoms in Dry Eye Disease | Q47611773 | ||
| Dry eye syndrome: developments and lifitegrast in perspective | Q47639135 | ||
| Alterations in corneal stromal dendritic cell phenotype and distribution in inflammation | Q47698171 | ||
| The Pathophysiology of Dry Eye Disease: What We Know and Future Directions for Research | Q47884949 | ||
| Ocular surface APCs are necessary for autoreactive T cell-mediated experimental autoimmune lacrimal keratoconjunctivitis. | Q50994458 | ||
| Corneal lymphangiogenesis facilitates ocular surface inflammation and cell trafficking in dry eye disease. | Q51732139 | ||
| Thymosin β4 significantly reduces the signs of dryness in a murine controlled adverse environment model of experimental dry eye. | Q53459932 | ||
| Closing the gap between T-cell life span estimates from stable isotope-labeling studies in mice and humans | Q59292898 | ||
| Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-α | Q59415968 | ||
| Dry Eye–Induced Conjunctival Epithelial Squamous Metaplasia Is Modulated by Interferon-γ | Q61851323 | ||
| Neutrophils cause obstruction of eyelid sebaceous glands in inflammatory eye disease in mice. | Q64889532 | ||
| Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1) | Q68202545 | ||
| Purification and structural characterization of LFA-1, a lymphocyte function-associated antigen, and Mac-1, a related macrophage differentiation antigen associated with the type three complement receptor | Q71439783 | ||
| Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes | Q73180482 | ||
| Prevalence of and risk factors for dry eye syndrome | Q74298539 | ||
| Inhibition of leukocyte sticking and infiltration, but not rolling, by antibodies to ICAM-1 and LFA-1 in murine endotoxin-induced uveitis | Q74582263 | ||
| Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine | Q77729873 | ||
| Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study | Q83540737 | ||
| Lifitegrast (Xiidra) for Dry Eye Disease | Q87809124 | ||
| Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast | Q89349313 | ||
| Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease | Q90972349 | ||
| Dry eye disease: an immune-mediated ocular surface disorder | Q36916372 | ||
| Chronic dry eye disease is principally mediated by effector memory Th17 cells | Q37067291 | ||
| Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression | Q37071969 | ||
| Prevalence, burden, and pharmacoeconomics of dry eye disease. | Q37152821 | ||
| Role of Th1 and Th17 cells in organ-specific autoimmunity. | Q37172965 | ||
| Induction, function and regulation of IL-17-producing T cells | Q37311131 | ||
| T helper cytokines in dry eye disease | Q37374838 | ||
| Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life | Q37715859 | ||
| Non-hormonal systemic medications and dry eye. | Q37949023 | ||
| Neutrophil arrest by LFA-1 activation | Q38018949 | ||
| Platelet function and thymosin β4. | Q38040257 | ||
| The role and treatment of inflammation in dry eye disease | Q38270449 | ||
| Glucocorticoid effects on NF-kappaB binding in the transcription of the ICAM-1 gene | Q38310590 | ||
| Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial | Q38414042 | ||
| Ocular Surface as Barrier of Innate Immunity | Q38544776 | ||
| Primary Mechanisms of Thymosin β4 Repair Activity in Dry Eye Disorders and Other Tissue Injuries | Q38560551 | ||
| TFOS DEWS II iatrogenic report. | Q38652981 | ||
| TFOS DEWS II pathophysiology report | Q38652987 | ||
| TFOS DEWS II Epidemiology Report | Q38652994 | ||
| TFOS DEWS II Sex, Gender, and Hormones Report. | Q38652997 | ||
| TFOS DEWS II Definition and Classification Report. | Q38665717 | ||
| Desiccating stress-induced disruption of ocular surface immune tolerance drives dry eye disease. | Q38810021 | ||
| LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease | Q39025675 | ||
| Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model | Q39188067 | ||
| TFOS DEWS II pain and sensation report. | Q39453338 | ||
| TFOS DEWS II Management and Therapy Report | Q39453364 | ||
| Inflamed lymphatic endothelium suppresses dendritic cell maturation and function via Mac-1/ICAM-1-dependent mechanism | Q39984665 | ||
| Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118) | Q40356553 | ||
| Systemic Comorbidities of Dry Eye Syndrome: The Korean National Health and Nutrition Examination Survey V, 2010 to 2012. | Q40406881 | ||
| Depression, Stress, Quality of Life, and Dry Eye Disease in Korean Women: A Population-Based Study | Q40910039 | ||
| Dry Eye Related to Commonly Used New Antidepressants | Q41669051 | ||
| Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group | Q41730611 | ||
| Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study | Q42708147 | ||
| Occludin gene expression as an early in vitro sign for mild eye irritation assessment | Q43281284 | ||
| Blocking CCR7 at the ocular surface impairs the pathogenic contribution of dendritic cells in allergic conjunctivitis | Q44491491 | ||
| ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice | Q44809776 | ||
| Comorbidities of dry eye disease: a nationwide population‐based study | Q44866954 | ||
| Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface | Q45158772 | ||
| Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca | Q45190856 | ||
| Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. | Q45950875 | ||
| P433 | issue | 3 | |
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 137-146 | |
| P577 | publication date | 2020-03-12 | |
| P1433 | published in | Journal of Ocular Pharmacology and Therapeutics | Q15755845 |
| P1476 | title | The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options | |
| P478 | volume | 36 |
Search more.